OTLK Outlook Therapeutics, Inc.
Price Chart
Executive Summary
Outlook Therapeutics resubmitted its Biologics License Application (BLA) for ONS-5010/LYTENAVA (bevacizumab-vikg) to the FDA for the treatment of neovascular age-related macular degeneration (nAMD). The FDA Office of New Drugs previously concluded that substantial evidence of effectiveness has been established, and this is a Class 1 resubmission with a PDUFA decision expected within 60 days.
Actionable Insight
The 60-day PDUFA clock creates a binary catalyst with a defined timeline. The FDA's prior conclusion that no additional trials are needed significantly de-risks approval. Monitor for labeling negotiations and any pre-approval inspection issues. The stock is likely to re-rate toward EU-approved product value ahead of the decision date.
Key Facts
- BLA resubmitted to FDA on June 1, 2026 for ONS-5010/LYTENAVA (bevacizumab-vikg) for nAMD.
- FDA Office of New Drugs concluded substantial evidence of effectiveness has been established; no additional trials required.
- Class 1 resubmission with PDUFA decision expected within 60 days of FDA receipt.
- Product already has Marketing Authorization in the EU and UK; commercial launch commenced in Germany, Austria, and the UK.
- If approved, ONS-5010 would be the first FDA-approved ophthalmic formulation of bevacizumab.
Financial Impact
No financial figures provided in the filing; market cap is $111M. FDA approval would open the U.S. market for the first on-label ophthalmic bevacizumab, a multi-billion-dollar opportunity in anti-VEGF retinal therapies.
Risk Factors
- FDA could issue a new Complete Response Letter on manufacturing or labeling issues despite the favorable appeal outcome.
- Pricing and reimbursement in the U.S. may be lower than expected, limiting revenue potential.
- Competition from existing anti-VEGF agents (Eylea, Vabysmo, Lucentis) and biosimilars may pressure market share.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-068659 |
| Document: tm2616461d1_ex99-1.htm | 0001104659-26-068659 |
| Document: 0001104659-26-068659-index-headers.html | 0001104659-26-068659 |
| Document: 0001104659-26-068659-index.html | 0001104659-26-068659 |
| Document: 0001104659-26-068659.txt | 0001104659-26-068659 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 3, 2026
9d ago
|
Insider Cluster
| $0.7950 $0.7767 | ▼ −2.30% | ▲ +0.27% | $1.22 (+53.46%) |
|
Jun 2, 2026
11d ago
|
Insider Cluster
| $0.8140 $0.8100 | ▼ −0.49% | ▲ +0.23% | $1.22 (+49.88%) |
|
Jun 1, 2026
11d ago
|
DEFA14A
| $0.8140 $0.8098 | ▲ +0.52% | ▼ −0.18% | $1.22 (−49.88%) |
|
Jun 1, 2026
11d ago
|
8-K
| $0.8430 $0.8140 | ▼ −3.44% | ▼ −3.58% | $1.22 (+44.72%) |
|
May 29, 2026
14d ago
|
8-K
| $0.8430 $0.8136 | ▲ +3.49% | ▲ +3.64% | $1.22 (−44.72%) |
|
May 29, 2026
14d ago
|
424B5
| $0.7300 $0.8430 | ▼ −15.48% | ▼ −15.20% | $1.22 (−67.12%) |
|
May 28, 2026
15d ago
|
8-K
| $0.7300 $0.8430 | ▼ −15.48% | ▼ −15.20% | $1.22 (−67.12%) |
|
May 28, 2026
15d ago
|
Press Release
| $0.7300 $0.8430 | ▼ −15.48% | ▼ −15.20% | $1.22 (−67.12%) |
|
May 27, 2026
16d ago
|
Insider Cluster
| $0.5860 $0.7400 | ▲ +26.28% | ▲ +25.73% | $1.22 (+108.19%) |
|
May 26, 2026
17d ago
|
Press Release
| $0.4000 $0.5860 | ▲ +46.50% | ▲ +46.49% | $1.22 (+205.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access